Commentary on the new 2022 European Society of Human Reproduction and Embryology (ESHRE) endometriosis guidelines

Eun Hee Yu, Jong Kil Joo

Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Pusan National University Hospital Medical Research Institute, Busan, Republic of Korea

Endometriosis is a prevalent benign illness defined by the presence of endometrial glands and stroma outside of the uterine cavity, primarily on the ovary, pelvic peritoneum, and rectovaginal septum [1]. It is linked to infertility and a variety of problems, including chronic pelvic pain, dysmenorrhea, deep dyspareunia, dysuria, dyschezia, and fatigue [2,3]. However, symptom severity is not usually proportional to the endometriosis stage, and some women with endometriosis may be asymptomatic.

Traditionally, endometriosis has been diagnosed through diagnostic laparoscopy or the histological identification of lesions. However, with recent developments in imaging modalities, the necessity for diagnostic laparoscopy in cases where endometriosis is relatively obvious has been questioned, and concerns have been raised regarding delays in the endometriosis diagnosis due to the diagnostic laparoscopic and histological confirmation criteria.

In 2022, the new European Society of Human Reproduction and Embryology (ESHRE) guidelines were published [4]. Although the new guidelines are not perfect, they provide clearer guidance on many difficult issues, such as medication selection among combined oral contraceptives (COCs), progestogen, and gonadotropin-releasing hormone (GnRH) agonists, and surgical indications for endometrioma in patients preparing for pregnancy.

The ESHRE guidelines are one of the most frequently cited endometriosis-related guidelines. It is believed that referring to representative changes in the new guidelines and major updates will be beneficial for diagnosing and treating endometriosis (Table 1). This paper provides a brief overview of these developments.
Diagnosis of endometriosis

The previous ESHRE guidelines suggested that laparoscopic histologic confirmation of endometriosis was the gold standard for an endometriosis diagnosis. In contrast, according to the new ESHRE guidelines, laparoscopy is no longer the diagnostic gold standard and is now only advised for patients with negative imaging results and/or when empirical treatment is ineffective or unsuitable. This change was based on a meta-analysis regarding endometriosis diagnostic tools. According to a Cochrane review, imaging modalities such as transvaginal ultrasonography and magnetic resonance imaging showed sensitivity and specificity for diagnosing endometrioma and deep endometriosis comparable to a surgical diagnosis (Table 2) [5]. As an added explanation in the new guidelines, the difficulties and limitations of making a noninvasive diagnosis of a superficial disease are described. Despite these limitations, stating that diagnostic laparoscopy is not the gold standard emphasizes the usefulness of imaging modalities for diagnosing endometrioma and deep endometriosis.

Treatment for endometriosis-associated pain

Discomfort related to endometriosis includes dysmenorrhea, dyspareunia, dysuria, dyschezia, and non-menstrual pelvic pain. In prior Korean and international guidelines, the hormonal medical treatment for endometriosis-associated pain has consisted of COCs, progestogens, anti-progestogens, aromatase inhibitors, and danazol. However, in the new guidelines, GnRH antagonists were introduced as a second treatment option, while anti-progestogens and danazol were withdrawn.

1. Introduction of GnRH antagonists as a second-line treatment option

The use of GnRH antagonists to alleviate endometriosis-associated pain can be considered. However, limited data exist on application of GnRH antagonist. Due to their side-effect profile, they are provided as a second-line option (for instance, if hormonal contraceptives or progestogens are ineffective). A study on two identical multi-center double-blind, randomized, placebo-controlled, phase 3 trials of 6-month treatments with oral elagolix at two doses in women with moderate

---

**Table 1. Summary of the latest guideline recommendation updates**

| Category                                      | Updates in the latest version                                                                 |
|-----------------------------------------------|-----------------------------------------------------------------------------------------------|
| Diagnosis of endometriosis                   | · Laparoscopy: no longer the diagnostic gold standard                                         |
| Treatment of endometriosis-associated pain   | · Consideration of a GnRH antagonist as a reasonable second-line treatment                    |
| Treatment of endometriosis-associated infertility | · Proceeding to postoperative medical treatment for expected benefits                        |
| Treatment of endometriosis-associated infertility | · Ultra-long protocol with GnRH agonist withdrawn from the evidence-based recommendations |
| Endometriosis recurrence                     | · Long-term hormone therapy advised when pregnancy is not desired                            |
| Endometriosis and adolescence                | · Newly added; diagnosis and management not significantly different from adults               |
| Endometriosis and menopause                  | · Importance reinforced; related symptoms present even in menopause                            |
| Primary prevention of endometriosis          | · Revised title from “prevention of endometriosis”; recurrence is dealt with separately in “endometriosis recurrence” |
| Endometriosis and cancer                     | · Association of endometriosis with certain cancer risks despite the low absolute risks in people with endometriosis relative to those without; additive reassurance recommended for endometriosis patients |

GnRH, gonadotropin-releasing hormone.

**Table 2. Accuracy of imaging modalities for endometriosis diagnosis**

| Type of endometriosis   | Modality | Number of patients included | Sensitivity (95% CI) | Specificity (95% CI) |
|-------------------------|----------|-----------------------------|----------------------|----------------------|
| Pelvic endometriosis    | TVUS     | 1,222 in 5 studies         | 0.65 (0.27–1.00)     | 0.95 (0.89–1.00)     |
|                         | MRI      | 396 in 10 data sets        | 0.79 (0.79–0.88)     | 0.72 (0.51–0.92)     |
| Ovarian endometrioma    | TVUS     | 765 in 8 studies           | 0.93 (0.87–0.99)     | 0.96 (0.92–0.99)     |
|                         | MRI      | 179 in 3 studies           | 0.95 (0.90–1.00)     | 0.91 (0.86–0.97)     |
| Deep endometriosis      | TVUS     | 1,383 in 12 data sets      | 0.79 (0.69–0.89)     | 0.94 (0.88–1.00)     |
|                         | MRI      | 289 in 7 data sets         | 0.94 (0.90–0.97)     | 0.77 (0.44–1.00)     |

CI, confidence interval; TVUS, transvaginal ultrasound; MRI, magnetic resonance imaging. Modified from Nisenblat et al. Cochrane Database Syst Rev 2016;2:CD009591 [5].

---

https://doi.org/10.5653/cerm.2022.05603
or severe endometriosis-associated pain provided data on treatment efficacy. The proportion of women who met the clinical response criteria for dysmenorrhea and non-menstrual pelvic pain was significantly higher among women who received each elagolix dose (46% in the lower-dose group, 75.8% in the higher-dose group) than among those who received placebo (19.6%). The reductions in dysmenorrhea and non-menstrual pelvic discomfort were noticeable after 1 month and persisted for 6 months. The most frequently reported adverse reactions were hot flushes, headaches, and nausea [6].

2. Changes in other medications

A levonorgestrel-releasing intrauterine system (LNG-IUS) has long been recognized as an effective treatment for endometriosis-associated discomfort. A recent randomized controlled trial (RCT) assigned 103 women with endometriosis-related chronic pelvic pain and/or dysmenorrhea to receive either an etonogestrel (ENG)-releasing subdermal implant or a 52-mg LNG-IUS [7]. Both the ENG implant and the LNG-IUS significantly reduced endometriosis-related pain, dysmenorrhea, and chronic pelvic pain. To alleviate endometriosis-related discomfort, it is recommended that women receive either an ENG implant or an LNG-IUS.

In addition, the Guideline Development Group (GDG) suggested using GnRH agonists as second-line treatments due to their side effect profile. Danazol and anti-progestogens, laparoscopic uterosacral neck ablation, presacral neurectomy, and anti-adhesion medications are no longer included in the recommendations of guidelines because of their harmful effects or lack of extra benefit.

3. Effectiveness of postoperative medical treatment

According to previous guidelines, practitioners should not provide adjunctive hormonal treatment for endometriosis-associated pain following surgery because it does not improve the outcomes of surgery to relieve pain. However, a recent Cochrane analysis by Chen et al. suggested that postsurgical medical therapy might reduce pain recurrence and illness recurrence within 12 months [8]. To improve the immediate success of surgery for pain in women with endometriosis who do not desire pregnancy, postoperative hormonal therapy may be administered.

Treatment of endometriosis-associated infertility

1. Introduction of the Endometriosis Fertility Index

The GDG recommends that the decision to perform surgery should be made in consideration of some factors such as the presence or absence of pain symptoms, patient age and preferences, history of previous surgery, presence of other infertility factors, ovarian reserve, and the estimated Endometriosis Fertility Index (EFI). The EFI was added to the new guidelines for the first time. The EFI staging system predicts non-in vitro fertilization pregnancy rates following surgical endometriosis staging and treatment [9]. The EFI is determined by historical variables (age, number of years of infertility, and prior pregnancy) and surgical variables (the American Society for Reproductive Medicine [ASRM] overall score, the ASRM endometriosis score, and the least function score).

2. No benefit of ultra-long GnRH agonist prior to assisted reproductive technology

The extended administration of a GnRH agonist prior to assisted reproductive technology treatment to increase the live birth rate in infertile women with endometriosis (ultra-long protocol) is no longer suggested due to the lack of evidence supporting its benefits.

The previous recommendation was based on an older Cochrane review regarding GnRH agonist pre-treatment, which included 228 patients from three studies and showed an increased likelihood of clinical pregnancy by more than 4-fold [10]. However, an updated Cochrane review that included eight parallel-design RCTs with a total of 640 participants, concluded that the effect of GnRH agonist pre-treatment (for at least 3 months) was very uncertain, both on the live birth rate as the primary outcome and on secondary outcomes (clinical pregnancy rate, multiple pregnancy rate, miscarriage rate, the mean number of oocytes, and the mean number of embryos) [11]. Another meta-analysis of studies comparing different GnRH agonist protocols (short, long, and ultra-long) also found that different down-regulation protocols did not significantly improve clinical outcomes (implantation rate, fertilization rate, and clinical pregnancy rate) by analyzing RCTs and observational studies (n = 21) [12].

3. Importance of fertility preservation

Prior ESHRE guidelines on fertility preservation considered benign disorders to be an indication for fertility preservation, but did not address whether endometriosis was a reason for fertility preservation in particular [13]. A recent large retrospective study by Cobo et al. [14] evaluated the outcome of fertility preservation utilizing vitrified oocytes in 485 patients with endometriomas of at least 1 cm and an antral follicular count of at least 3, finding oocyte survival rates of 83.2% after warming and a cumulative live birth rate of 46.4%. They concluded that fertility preservation was a valid treatment option in patients with endometriosis. Although several issues such as cost-effectiveness and specific indications remain unsolved, practitioners should explore the advantages and disadvantages of fertility preservation with endometriosis patients who have severe ovarian endometriosis.
4. Impact of endometriosis on pregnancy and pregnancy outcomes

Sparse data with low and moderate quality indicated that the behavior of endometriotic lesions during pregnancy was diverse, ranging from complete elimination to increasing growth [15]. Patients should not be encouraged to become pregnant with the primary aim of treating endometriosis because pregnancy does not necessarily result in symptom improvements or slow disease progression. The decidualization of an endometrioma during pregnancy may resemble malignant ovarian tumors in some circumstances, providing a diagnostic conundrum. However, the incidence of this event is unknown (0%-12% prevalence, 17 studies reporting 60 cases) [16]. Endometrioma can manifest differently throughout pregnancy. If an ultrasound examination during pregnancy reveals atypical endometrioma, it is recommended that the patient be referred to a center with the necessary expertise.

Complications directly connected to pre-existing endometriosis lesions are uncommon and likely underreported. These issues may result from decidualization, adhesion formation/stretching, and endometriosis-related chronic inflammation [16]. Although uncommon, these may pose life-threatening conditions that necessitate surgical treatment. Clinicians should be aware that women with endometriosis may have a higher risk of miscarriages and ectopic pregnancies during the first trimester. They should also be informed of uncommon endometriosis-related problems during pregnancy, which include gestational diabetes, preterm birth, premature rupture of membranes, placenta previa, hypertensive disorders and pre-eclampsia, stillbirth, cesarean section, obstetric hemorrhage (placental abruption, antepartum and postpartum bleeding), small for gestational age, admission to the neonatal intensive care unit, and neonatal death. However, since these results are based on low- or moderate-quality research, they should be regarded with caution, and additional antenatal monitoring is not recommended.

Endometriosis recurrence

The recurrence rate of endometriosis has been reported to range from 0% to 89.6% [17]. This variation could be related to differences in the definitions of recurrence, length of follow-up, study design, sample size, type and stage of disease, type of operation, and postoperative medical care [17]. As the high recurrence rate and its significance have been consistently emphasized, they are described in a separate chapter, unlike in the earlier guidelines. For preventing recurrence, ovarian cystectomy instead of drainage/electrocoagulation and postoperative hormonal treatment for at least 18 to 24 months are recommended. The recommended duration of hormonal treatment is based on RCTs. However, in patients who are not immediately seeking conception, long-term hormonal therapy is recommended.

Endometriosis and adolescence

There are scarce data on endometriosis and adolescence. Although there are no major differences between the diagnosis and treatment of endometriosis in adolescents and adults, clinicians treating adolescents should be vigilant regarding several factors. Not only is dysmenorrhea a major symptom of endometriosis, but it is also a highly prevalent occurrence in adolescents, and it takes significantly longer to reach a diagnosis of endometriosis in adolescents than in adults. When previous treatments have failed, clinicians may consider prescribing a GnRH agonist for up to 1 year. If GnRH agonist treatment is considered for young women and adolescents, it should be delivered only after careful evaluation and a discussion of potential adverse effects and long-term health problems with a practitioner in a secondary or tertiary care setting, as recommended by the GDG. As with adults, no studies have addressed the efficacy or utility of fertility preservation—specifically, oocyte cryopreservation—in adolescents with endometriosis. Although the true benefits, safety, and indications for adolescents with endometriosis remain unknown, the GDG recommends informing adolescents about fertility preservation options.

Endometriosis and menopause

The amount of data available regarding the prevalence of endometriosis after menopause is extremely limited. A recent retrospective cohort study described a 4% prevalence of postmenopausal endometriosis [18]. It is hypothesized that menopausal hormone therapy can increase the formation of endometriosis [19] and a variety of factors, some of which are unknown, can also affect the growth of endometriosis. Therefore, it is important for clinicians to be aware that endometriosis might continue to be active and cause symptoms after menopause.

For postmenopausal women presenting with signs of endometriosis and/or discomfort, clinicians might consider surgical treatment as a means of enabling histological confirmation of the diagnosis of endometriosis. The GDG suggests that practitioners emphasize the ambiguity regarding the risk of cancer in postmenopausal women. If a mass is found in the pelvis, a diagnostic workup and treatment should be carried out in accordance with the national oncology standards. Clinicians may consider aromatase inhibitors as a potential therapeutic option for endometriosis-related pain in postmenopausal women, particularly if surgery is not a viable option.

Clinicians should be aware that women with endometriosis who undergo early bilateral salpingo-oophorectomy as part of their ther-
apy have a higher risk of decreased bone density, dementia, and cardiovascular disease. It is also essential to emphasize that women with endometriosis have a higher risk of cardiovascular disease, regardless of whether they have undergone early surgical menopause.

For the management of postmenopausal symptoms in women with a history of endometriosis, combined menopausal hormone therapy may be considered; however, tibolone is no longer recommended as a medical treatment for menopausal symptoms in women with a history of endometriosis.

**Extra-pelvic endometriosis**

Clinicians should be aware of the symptoms of extra-pelvic endometriosis, which include cyclical shoulder discomfort, cyclical spontaneous pneumothorax, cyclical cough, and enlargement of nodules during menstruation. The diagnosis and treatment of extra-pelvic endometriosis should be discussed by a multidisciplinary team at an institution with sufficient expertise. When possible, surgical excision is the best treatment for alleviating symptoms in women with abdominal extra-pelvic endometriosis. If surgery is inapplicable or unacceptable, hormonal therapy may also be an alternative.

**Asymptomatic endometriosis**

Clinicians should not regularly perform surgical excision/ablation for asymptomatic endometriosis discovered incidentally during surgery. Practitioners should not suggest medical therapy to women with an incidental endometriosis diagnosis, but routine ultrasound surveillance must be recommended. Even in the absence of convincing data on the benefits of monitoring asymptomatic endometriosis, the GDG recommends considering ultrasound surveillance due to its low cost and safety.

**Primary prevention of endometriosis**

The objective of primary prevention is to prevent healthy and asymptomatic women from developing endometriosis. Although there is no direct proof of the efficacy of a healthy lifestyle and diet in preventing endometriosis, women can be counseled to adopt a healthy lifestyle and diet, including reduced alcohol use and regular physical activity. The efficacy of hormonal contraceptives for the primary prevention of endometriosis is uncertain. Genetic testing of women with suspected or proven endometriosis should only be undertaken in a research context, citing the newly added text.

**Endometriosis and cancer**

According to the 2014 recommendations, ovarian cancer and non-Hodgkin lymphoma were slightly prevalent among endometriosis patients. Nevertheless, according to a recent systematic review and meta-analysis of 49 cohort or case-control studies, endometriosis was related to a very slight and not statistically significant higher risk of cancer overall (summary relative risk [SRR], 1.07; 95% confidence interval [CI], 0.96–1.16) [20]. Endometriosis was related to an increased risk of ovarian cancer (SRR, 1.93), especially clear-cell (SRR, 3.44) and endometrioid (SRR, 2.33) histotypes, breast cancer (SRR, 1.04) and thyroid cancer (SRR, 1.39) [20]. Although endometriosis is associated with an elevated risk of certain cancers, given the low absolute risks of ovarian, breast, and thyroid cancer in people with endometriosis relative to those without (increases of 1.2%p, 0.5%p, and 0.5%p, respectively) and the uncertainty regarding the risk of other cancers, endometriosis patients can be reassured that their cancer risk is low and comparable to that of people without the disease. Clinicians should educate women with endometriosis who request information on their cancer risk that endometriosis is not associated with an increased risk of cancer. Although endometriosis is related to a somewhat higher risk of ovarian, breast, and thyroid malignancies, the absolute increase in risk relative to the general female population is minimal (Table 3).

**Conclusion**

The new ESHRE recommendations are clearer and more practical than their predecessors and other guidelines. However, as stated on the opening page of the ESHRE guidelines, clinical practice guidelines do not supersede the clinical decisions made by a healthcare professional for diagnosis and treatment. Ultimately, healthcare professionals must make their own clinical decisions case by case, with consideration of various circumstances.

| Table 3. Absolute risk for cancer in women with endometriosis [4] |
|--------------------------------------------------------------|
| **Variable** | **Absolute risk of developing cancer in a woman’s lifetime (%)** | **Increase in risk in women with endometriosis (%)** |
|---------------|---------------------------------------------------------------|-------------------------------------------------|
| Ovarian cancer | All women 1.3 | Women with endometriosis 2.5 | +1.2 |
| Breast cancer  | All women 12.8 | Women with endometriosis 13.3 | +0.5 |
| Thyroid cancer | All women 1.3 | Women with endometriosis 1.8 | +0.5 |

www.eCERM.org
**Conflict of interest**

Jong Kil Joo is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article.

No other potential conflicts of interest relevant to this article were reported.

**ORCID**

Eun Hee Yu  https://https://orcid.org/0000-0002-0249-0467  
Jong Kil Joo  https://https://orcid.org/0000-0002-6338-1512

**Author contributions**

Writing–original draft: all authors. Writing–review and editing: JKJ.

**References**

1. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012;98:511–9.
2. Nnoaham KE, Hummelshoj L, Webster P, d’Hooghe T, de Cicco Nardone F, de Cicco Nardone C, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril 2011;96:366–73.
3. Rush G, Misajon R, Hunter JA, Gardner J, O’Brien KS. The relationship between endometriosis-related pelvic pain and symptom frequency, and subjective wellbeing. Health Qual Life Outcomes 2019;17:123.
4. Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, et al. ESHRE guideline: endometriosis. Hum Reprod Open 2022;2022:hoac009.
5. Nisenblat V, Bossuyt PM, Farquhar C, Johnson N, Hull ML. Imaging modalities for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev 2016;2:CD009591.
6. Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of endometriosis-associated pain with Elagolix, an oral GnRH antagonist. N Engl J Med 2017;377:28–40.
7. Margatho D, Carvalho NM, Bahamondes L. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months. Eur J Contracept Reprod Health Care 2020;25:133–40.
8. Chen I, Veth VB, Choudhry AJ, Murji A, Zakhari A, Black AY, et al. Pre- and postsurgical medical therapy for endometriosis surgery. Cochrane Database Syst Rev 2020;11:CD003678.
9. Adamson GD, Pasta DJ. Endometriosis fertility index: the new, validated endometriosis staging system. Fertil Steril 2010;94:1609–15.
10. Sallam HN, Garcia-Velasco JA, Dias S, Arici A. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev 2006;2006:CD004635.
11. Georgiou EX, Melo P, Baker PE, Sallam HN, Arici A, Garcia-Velasco JA, et al. Long-term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with endometriosis. Cochrane Database Syst Rev 2019;2019:CD013240.
12. Cao X, Chang HY, Xu JY, Zheng Y, Xiang YG, Xiao B, et al. The effectiveness of different down-regulating protocols on in vitro fertilization-embryo transfer in endometriosis: a meta-analysis. Reprod Biol Endocrinol 2020;18:16.
13. ESHRE Guideline Group on Female Fertility Preservation; Anderson RA, Amant F, Braat D, D’Angelo A, Chuva de Sousa Lopes SM, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open 2020;2020:hoaa052.
14. Cobo A, Giles J, Paolelli S, Pellicer A, Remohi J, Garcia-Velasco JA. Oocyte vitrification for fertility preservation in women with endometriosis: an observational study. Fertil Steril 2020;113:836–44.
15. Leeners B, Damaso F, Ochsenbein-Kolble N, Farquhar C. The effect of pregnancy on endometriosis-facts or fiction? Hum Reprod Update 2018;24:290–9.
16. Leone Roberti Maggiore U, Ferrero S, Mangili G, Bergamini A, Inversetti A, Giorgione V, et al. A systematic review on endometriosis during pregnancy: diagnosis, misdiagnosis, complications and outcomes. Hum Reprod Update 2016;22:70–103.
17. Ceccaroni M, Bounous VE, Clarizia R, Mautone D, Mabrouk M. Recurrent endometriosis: a battle against an unknown enemy. Eur J Contracept Reprod Health Care 2019;24:464–74.
18. Matalliotakis M, Matalliotaki C, Trivli A, Zervou MI, Kalogiannidis I, Tzardi M, et al. Keeping an eye on perimenopausal and postmenopausal endometriosis. Diseases 2019;7:29.
19. Gemmell LC, Webster KE, Kirtley S, Vincent K, Zondervan KT, Becker CM. The management of menopause in women with a history of endometriosis: a systematic review. Hum Reprod Update 2017;23:481–500.
20. Kvasoff M, Mahamat-Saleh Y, Farland LV, Shigesi N, Terry KL, Harris HR, et al. Endometriosis and cancer: a systematic review and meta-analysis. Hum Reprod Update 2021;27:393–420.